Tina S. Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tina S. Morris has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Bernardetta Nardelli
2 shared publicationsYuling Li
2 shared publicationsZachary Shriver
Department of Biological Engineering, Harvard-MIT Division of Health Sciences &Technology, Koch institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
2 shared publicationsA Daas
1 shared publicationA Heath
1 shared publicationAdrian F. Bristow
National Institute for Biological Standards and Control
1 shared publication
Latest Publications
- 9 June 2016
- Published by Springer Nature in Nature Biotechnology
- Vol. 34 (6) , 625-630
The US regulatory and pharmacopeia response to the global heparin contamination crisis
The contamination of the widely used lifesaving anticoagulant drug heparin in 2007 has drawn renewed attention to the challenges that are associated with the characterization, quality control and standardization of complex biological medicines from natural sources. Heparin is a linear, highly sulfated polysaccharide consisting of alternating glucosamine and uronic acid monosaccharide residues. Heparin has been used successfully as an injectable antithrombotic medicine since the 1930s, and its isolation from animal sources (primarily porcine intestine) as well as its manufacturing processes have not changed substantially since its introduction. The 2007 heparin contamination crisis resulted in several deaths in the United States and hundreds of adverse reactions worldwide, revealing the vulnerability of a complex global supply chain to sophisticated adulteration. This Perspective discusses how the US Food and Drug Administration (FDA), the United States Pharmacopeial Convention (USP) and international stakeholders collaborated to redefine quality expectations for heparin, thus making an important natural product better controlled and less susceptible to economically motivated adulteration.
- 9 June 2016
- Published by Springer Nature in Nature Biotechnology
- Vol. 34 (6) , 625-630
The US regulatory and pharmacopeia response to the global heparin contamination crisis
The contamination of the widely used lifesaving anticoagulant drug heparin in 2007 has drawn renewed attention to the challenges that are associated with the characterization, quality control and standardization of complex biological medicines from natural sources. Heparin is a linear, highly sulfated polysaccharide consisting of alternating glucosamine and uronic acid monosaccharide residues. Heparin has been used successfully as an injectable antithrombotic medicine since the 1930s, and its isolation from animal sources (primarily porcine intestine) as well as its manufacturing processes have not changed substantially since its introduction. The 2007 heparin contamination crisis resulted in several deaths in the United States and hundreds of adverse reactions worldwide, revealing the vulnerability of a complex global supply chain to sophisticated adulteration. This Perspective discusses how the US Food and Drug Administration (FDA), the United States Pharmacopeial Convention (USP) and international stakeholders collaborated to redefine quality expectations for heparin, thus making an important natural product better controlled and less susceptible to economically motivated adulteration.
- 1 January 2015
- Vol. 2015, 73-98
Collaborative study for the establishment of the WHO 3(rd) International Standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354.
An international collaborative study was organised jointly by the World Health Organization (WHO)/National Institute for Biological Standards and Control (NIBSC), the United States Pharmacopeia (USP) and the European Directorate for the Quality of Medicines & HealthCare (EDQM/Council of Europe) for the establishment of harmonised replacement endotoxin standards for these 3 organisations. Thirty-five laboratories worldwide, including Official Medicines Control Laboratories (OMCLs) and manufacturers enrolled in the study. Three candidate preparations (10/178, 10/190 and 10/196) were produced with the same material and same formulation as the current reference standards with the objective of generating a new (3(rd)) International Standard (IS) with the same potency (10 000 IU/vial) as the current (2(nd)) IS, as well as new European Pharmacopoeia (Ph. Eur.). and USP standards. The suitability of the candidate preparations to act as the reference standard in assays for endotoxin performed according to compendial methods was evaluated. Their potency was calibrated against the WHO 2(nd) IS for Endotoxin (94/580). Gelation and photometric methods produced similar results for each of the candidate preparations. The overall potency estimates for the 3 batches were comparable. Given the intrinsic assay precision, the observed differences between the batches may be considered unimportant for the intended use of these materials. Overall, these results were in line with those generated for the establishment of the current preparations of reference standards. Accelerated degradation testing of vials stored at elevated temperatures supported the long-term stability of the 3 candidate preparations. It was agreed between the 3 organisations that batch 10/178 be shared between WHO and EDQM and that batches 10/190 and 10/196 be allocated to USP, with a common assigned value of 10 000 IU/vial. This value maintains the continuity of the global harmonisation of reference materials and unitage for the testing of endotoxins in parenteral pharmaceutical products. Based on the results of the collaborative study, batch 10/178 was established by the European Pharmacopoeia Commission as the Ph. Eur. Endotoxin Biological Reference Preparation (BRP) batch 5. The same batch was also established by the Expert Committee on Biological Standardisation (ECBS) of WHO as the WHO 3(rd) IS for Endotoxin. Batch 10/190 was adopted as the USP Endotoxin Reference Standard, lot H0K354 and vials from this same batch (10/190) will serve as the United States Food and Drug Administration (USFDA) Endotoxin Standard, EC-7.
- 1 January 2015
- Vol. 2015, 73-98
Collaborative study for the establishment of the WHO 3(rd) International Standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354.
An international collaborative study was organised jointly by the World Health Organization (WHO)/National Institute for Biological Standards and Control (NIBSC), the United States Pharmacopeia (USP) and the European Directorate for the Quality of Medicines & HealthCare (EDQM/Council of Europe) for the establishment of harmonised replacement endotoxin standards for these 3 organisations. Thirty-five laboratories worldwide, including Official Medicines Control Laboratories (OMCLs) and manufacturers enrolled in the study. Three candidate preparations (10/178, 10/190 and 10/196) were produced with the same material and same formulation as the current reference standards with the objective of generating a new (3(rd)) International Standard (IS) with the same potency (10 000 IU/vial) as the current (2(nd)) IS, as well as new European Pharmacopoeia (Ph. Eur.). and USP standards. The suitability of the candidate preparations to act as the reference standard in assays for endotoxin performed according to compendial methods was evaluated. Their potency was calibrated against the WHO 2(nd) IS for Endotoxin (94/580). Gelation and photometric methods produced similar results for each of the candidate preparations. The overall potency estimates for the 3 batches were comparable. Given the intrinsic assay precision, the observed differences between the batches may be considered unimportant for the intended use of these materials. Overall, these results were in line with those generated for the establishment of the current preparations of reference standards. Accelerated degradation testing of vials stored at elevated temperatures supported the long-term stability of the 3 candidate preparations. It was agreed between the 3 organisations that batch 10/178 be shared between WHO and EDQM and that batches 10/190 and 10/196 be allocated to USP, with a common assigned value of 10 000 IU/vial. This value maintains the continuity of the global harmonisation of reference materials and unitage for the testing of endotoxins in parenteral pharmaceutical products. Based on the results of the collaborative study, batch 10/178 was established by the European Pharmacopoeia Commission as the Ph. Eur. Endotoxin Biological Reference Preparation (BRP) batch 5. The same batch was also established by the Expert Committee on Biological Standardisation (ECBS) of WHO as the WHO 3(rd) IS for Endotoxin. Batch 10/190 was adopted as the USP Endotoxin Reference Standard, lot H0K354 and vials from this same batch (10/190) will serve as the United States Food and Drug Administration (USFDA) Endotoxin Standard, EC-7.
- 24 June 2014
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 406 (20) , 4815-4823
USP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium
- 24 June 2014
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 406 (20) , 4815-4823
USP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium
- 2 April 2014
- Published by Springer Nature in The AAPS Journal
- Vol. 16 (3) , 516-521
Role of Public Standards in the Safety and Efficacy of Biologic Medicines
In this report, we emphasize the importance of public monographs with reference materials, coupled with careful process and change control and attention to GMPs, as a means of advancing access to good quality, safe, and effective medicines, with emphasis on available and incoming biologic medicines. With adequate control of articles covered by a monograph, these public standards can form the basis for a global public quality platform that covers reference products, non-interchangeable reference products, biosimilars, and interchangeable biosimilars. Working collaboratively with all stakeholders, new approaches allow these public standards to emerge nationally and globally in a timely way. Yet, there are increasing limitations in the availability of public standards for biologic medicines, which may reverse many decades of progress. Solutions are considered in this report.
- 2 April 2014
- Published by Springer Nature in The AAPS Journal
- Vol. 16 (3) , 516-521
Role of Public Standards in the Safety and Efficacy of Biologic Medicines
In this report, we emphasize the importance of public monographs with reference materials, coupled with careful process and change control and attention to GMPs, as a means of advancing access to good quality, safe, and effective medicines, with emphasis on available and incoming biologic medicines. With adequate control of articles covered by a monograph, these public standards can form the basis for a global public quality platform that covers reference products, non-interchangeable reference products, biosimilars, and interchangeable biosimilars. Working collaboratively with all stakeholders, new approaches allow these public standards to emerge nationally and globally in a timely way. Yet, there are increasing limitations in the availability of public standards for biologic medicines, which may reverse many decades of progress. Solutions are considered in this report.
- 1 October 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (18) , 60-61
USP Improves Biologic Quality Standards
- 1 October 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (18) , 60-61
USP Improves Biologic Quality Standards
- 14 July 2011
- Published by Taylor & Francis in Bioanalysis
- Vol. 3 (14) , 1547-1549
Role of Public Quality Standards for Biological Medicines
- 14 July 2011
- Published by Taylor & Francis in Bioanalysis
- Vol. 3 (14) , 1547-1549
Role of Public Quality Standards for Biological Medicines
- 1 March 2006
- Published by Wiley in Agronomy Journal
- Vol. 98 (2) , 280-288
Soil Test Calibration for Predicting Corn Response to Phosphorus in the Northeast USA
The consensus of soil fertility specialists working in the northeast USA was that soil testing and recommendation systems for P needed to be reexamined because of recent changes in soil testing methodology in the laboratory and corn (Zea mays L.) production technology in the field. Soil tests (M‐COL, MM‐COL, B‐ICP, M1‐ICP, and M3‐ICP) were performed by either colorimetry or inductively coupled plasma (ICP) emission spectroscopy on samples from soil test calibration studies conducted during 1998 to 1999 at 51 experimental sites chosen to represent a range of soils, including Ultisols, Spodosols, and Alfisols, in northeastern states (Connecticut, Delaware, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, and West Virginia). The mean P measured by M‐COL, MM‐COL, B‐ICP, M1‐ICP, and M3‐ICP was 8.3, 6.6, 148, 66, and 121 mg P kg−1, respectively. Production practices followed local state extension recommendations at each site and included P fertilizer treatments: none, 15 kg P ha−1 banded, or 60 kg P ha−1 broadcast. Combined analysis of variance over sites showed that plant height at 35 d after planting, silk emergence, grain yield, and grain dry down were enhanced by the broadcast P treatment. There were yield increases (P < 0.10) to the band treatment at only four sites and to the broadcast treatment at nine sites. Cate‐Nelson statistical analysis of relative yield in relation to soil test P failed to identify soil test P critical levels for any of the soil test methods. The percentage of experimental sites that had soil test P levels below the currently used critical levels in the region ranged from 14 to 65% of the sites. Results showed that 17 to 47% of those sites testing below the critical level exhibited a yield increase (P < 0.10) to broadcast P. Some of the yield responsive sites had soil test P above currently used critical levels. The calibration data obtained from the present study and the relationships examined between soil test P and relative yield do not necessarily validate the currently used soil test P critical levels nor does the data enable much refinement. This study shows that the current critical levels frequently permit both types of errors in soil test prediction; indicating a need for P fertilization when it may not be needed and not indicating a need for P fertilization when it may be needed. The second type of error is usually avoided by recommendations for crop removal rates of P.
- 1 March 2006
- Published by Wiley in Agronomy Journal
- Vol. 98 (2) , 280-288
Soil Test Calibration for Predicting Corn Response to Phosphorus in the Northeast USA
The consensus of soil fertility specialists working in the northeast USA was that soil testing and recommendation systems for P needed to be reexamined because of recent changes in soil testing methodology in the laboratory and corn (Zea mays L.) production technology in the field. Soil tests (M‐COL, MM‐COL, B‐ICP, M1‐ICP, and M3‐ICP) were performed by either colorimetry or inductively coupled plasma (ICP) emission spectroscopy on samples from soil test calibration studies conducted during 1998 to 1999 at 51 experimental sites chosen to represent a range of soils, including Ultisols, Spodosols, and Alfisols, in northeastern states (Connecticut, Delaware, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, and West Virginia). The mean P measured by M‐COL, MM‐COL, B‐ICP, M1‐ICP, and M3‐ICP was 8.3, 6.6, 148, 66, and 121 mg P kg−1, respectively. Production practices followed local state extension recommendations at each site and included P fertilizer treatments: none, 15 kg P ha−1 banded, or 60 kg P ha−1 broadcast. Combined analysis of variance over sites showed that plant height at 35 d after planting, silk emergence, grain yield, and grain dry down were enhanced by the broadcast P treatment. There were yield increases (P < 0.10) to the band treatment at only four sites and to the broadcast treatment at nine sites. Cate‐Nelson statistical analysis of relative yield in relation to soil test P failed to identify soil test P critical levels for any of the soil test methods. The percentage of experimental sites that had soil test P levels below the currently used critical levels in the region ranged from 14 to 65% of the sites. Results showed that 17 to 47% of those sites testing below the critical level exhibited a yield increase (P < 0.10) to broadcast P. Some of the yield responsive sites had soil test P above currently used critical levels. The calibration data obtained from the present study and the relationships examined between soil test P and relative yield do not necessarily validate the currently used soil test P critical levels nor does the data enable much refinement. This study shows that the current critical levels frequently permit both types of errors in soil test prediction; indicating a need for P fertilization when it may not be needed and not indicating a need for P fertilization when it may be needed. The second type of error is usually avoided by recommendations for crop removal rates of P.
- 25 February 2002
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 9 (4) , 288-292
Structural basis of BLyS receptor recognition
B lymphocyte stimulator (BLyS), a member of the tumor necrosis factor (TNF) superfamily, is a cytokine that induces B-cell proliferation and immunoglobulin secretion. We have determined the three-dimensional structure of BLyS to 2.0 A resolution and identified receptor recognition segments using limited proteolysis coupled with mass spectrometry. Similar to other structurally determined TNF-like ligands, the BLyS monomer is a beta-sandwich and oligomerizes to form a homotrimer. The receptor-binding region in BLyS is a deeper, more pronounced groove than in other cytokines. The conserved elements on the 'floor' of this groove allow for cytokine recognition of several structurally related receptors, whereas variations on the 'walls' and outer rims of the groove confer receptor specificity.
- 25 February 2002
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 9 (4) , 288-292
Structural basis of BLyS receptor recognition
B lymphocyte stimulator (BLyS), a member of the tumor necrosis factor (TNF) superfamily, is a cytokine that induces B-cell proliferation and immunoglobulin secretion. We have determined the three-dimensional structure of BLyS to 2.0 A resolution and identified receptor recognition segments using limited proteolysis coupled with mass spectrometry. Similar to other structurally determined TNF-like ligands, the BLyS monomer is a beta-sandwich and oligomerizes to form a homotrimer. The receptor-binding region in BLyS is a deeper, more pronounced groove than in other cytokines. The conserved elements on the 'floor' of this groove allow for cytokine recognition of several structurally related receptors, whereas variations on the 'walls' and outer rims of the groove confer receptor specificity.